Orchestra BioMed Holdings, Inc. (OBIO) SEC Filings & Earnings Calls

Trial results still pending; primary endpoint data expected Q2 2027.

“Primary endpoint data to be submitted for late-breaking presentation in Q2 2027.”

Clinical and regulatory risk for pipeline programs; no approved products yet.

“Pivotal trials still enrolling; FDA approval not guaranteed.”

Clinical Trial Execution Risk

“We cannot provide assurance that we will be able to complete enrollment of the BACKBEAT Trial or the Virtue Trial in the timeframes we anticipate.” · word for word

Going Concern / Capital Need

“Our future viability is dependent on our ability to raise additional capital to finance our operations.” · word for word

High Debt Cost

“Our estimate of this total interest expense associated with the Royalty Interest resulted in an effective annual interest rate of approximately 21.2% as of June 30, 2026.” · word for word

Clinical trial failure/delay risk

“We cannot provide assurance that we will be able to complete enrollment of the BACKBEAT Trial or the Virtue Trial in the timeframes we anticipate.” · word for word

Cash burn / going concern risk

“We have incurred net losses each year since inception. ... We expect to continue to incur significant losses for the foreseeable future.”

Dilution risk from at-the-market offering

“As of the date of this Quarterly Report on Form 10-Q, we may sell up to $92.4 million of shares of our common stock under the sales agreement ...” · word for word

High effective interest rate on debt/royalty financing

“Our estimate of this total interest expense associated with the Royalty Interest resulted in an effective annual interest rate of approximately 23.3% as of March 31, 2026.” · word for word

Clinical trial execution risk

“For 2025, 100% of 2025 Incentive Bonus Plan payments for Messrs. Hochman and Sherman were based on progress made relating to the following corporate goals and objectives approved by the Compensation Committee (the '2025 Corporate Goals and Objectives'): achieving certain enrollment targets with respect to the BACKBEAT study and achieving certain other milest”

Dependence on Medtronic partnership

“Under the terms of the Medtronic Agreement, Medtronic, Inc. will have exclusive rights in the Primary Field to commercialize AVIM-enabled pacing systems globally following receipt of regulatory approvals. Medtronic, Inc. would be entirely responsible for global commercialization following any receipt of regulatory approvals, including manufacturing, sales, m”

Clinical trial failure risk

“The clinical study process required to obtain regulatory approvals or certifications carries substantial risks and is lengthy and expensive with uncertain outcomes. If our clinical studies are unsuccessful or significantly delayed, or if we do not complete our clinical studies, our business may be harmed.” · word for word

Dependence on partners

“We are, and expect to continue to be, highly dependent on partners to drive the successful marketing and sale of our initial product candidates. There is no assurance that we will be able to form and properly manage partnerships. There is no assurance that partnerships will be successful.” · word for word

History of losses and need for future capital

“We have a history of net losses, and we expect to continue to incur losses for the foreseeable future. If we ever achieve profitability, we may not be able to sustain it. Our ability to timely raise capital in the future may be limited, or may be unavailable on acceptable terms, if at all.” · word for word

Patent expiration risk

“Our issued patents expire between March 2026 and April 2041. Despite the near-term expiration of certain of our material patents, we believe that our other patents, as well as our trade secrets and continuing technological know-how, provide us with sufficient intellectual property protection to develop our product candidates and protect our intellectual prop”

Clinical trial enrollment delay risk

“We cannot provide assurance that we will be able to complete enrollment of the BACKBEAT study or the Virtue Trial in the timeframes we anticipate.” · word for word

Share overhang from resale registration

“The registration of these shares of Company Common Stock for resale creates the possibility of a significant increase in the supply of the Company Common Stock in the market.” · word for word